Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a


Autoria(s): Moreau, Isabelle; Levis, John; Crosbie, Orla; Kenny-Walsh, Elizabeth; Fanning, Liam J.
Data(s)

17/06/2016

17/06/2016

09/07/2008

18/01/2013

Resumo

Pre-treatment HCV quasispecies complexity and diversity may predict response to interferon based anti-viral therapy. The objective of this study was to retrospectively (1) examine temporal changes in quasispecies prior to the start of therapy and (2) investigate extensively quasispecies evolution in a group of 10 chronically infected patients with genotype 3a, treated with pegylated alpha 2a-Interferon and ribavirin. The degree of sequence heterogeneity within the hypervariable region 1 was assessed by analyzing 20-30 individual clones in serial serum samples. Genetic parameters, including amino acid Shannon entropy, Hamming distance and genetic distance were calculated for each sample. Treatment outcome was divided into (1) sustained virological responders (SVR) and (2) treatment failure (TF).Our results indicate, (1) quasispecies complexity and diversity are lower in the SVR group, (2) quasispecies vary temporally and (3) genetic heterogeneity at baseline can be used to predict treatment outcome. We discuss the results from the perspective of replicative homeostasis. We discuss the results from the perspective of replicative homeostasis.

Formato

application/pdf

Identificador

Moreau, I., Levis, J., Crosbie, O., Kenny-Walsh, E. and Fanning, L. J. (2008) 'Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a', Virology Journal, 5: 78. http://dx.doi.org/10.1186/1743-422X-5-78

5

1

15

1743-422X

http://hdl.handle.net/10468/2755

10.1186/1743-422X-5-78

Virology Journal

78

Idioma(s)

en

Publicador

Biomed Central

Direitos

© 2008 Moreau et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

http://creativecommons.org/licenses/by/2.0/

Palavras-Chave #Hepatitis C virus #Interferon-alpha-2b plus ribavirin #Hypervariable region 1 #Antiviral therapy #Replicative homeostasis #Pegylated interferon #Sequence variability #Genetic diversity #Immune selection #Envelope protein
Tipo

Article (peer-reviewed)